Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of mini-CHOP plus ofatumumab in patients over 80 years with CD20-positive diffuse large B-cell lymphoma
2009-017995-26Phase 2Completed
- Sponsor
- GELARC
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in diffuse large B-cell lymphoma (DLBCL), sponsored by GELARC. Primary endpoint: Overall survival. Started Mar 2010; status: completed.
02
Drugs
ofatumumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2009-017995-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017995-26.